<DOC>
	<DOCNO>NCT00782756</DOCNO>
	<brief_summary>The purpose study test safety new plan treat glioblastoma . The usual first treatment glioblastoma give focus radiation 6 week combination chemotherapy call temozolomide . In study radiation give 2 week combination temozolomide another drug , bevacizumab , also give . Our idea treatment plan may attack tumor blood vessel feed tumor effectively . This study look effect , good bad , approach patient tumor .</brief_summary>
	<brief_title>Bevacizumab , Temozolomide Hypofractionated Radiotherapy Patients With Newly Diagnosed Malignant Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Pathologic diagnosis glioblastoma grade IV glioma . Tumor volume le 60 cc ( approximately 5cm maximum diameter ) . Age &gt; = 18 KPS ≥70 Granulocyte count &gt; 1.5 X 10 9/L Platelet count &gt; 99 X 10 9/L SGOT &lt; 2.5X upper limit normal ( ULN ) Serum creatinine &lt; 2X ULN Bilirubin &lt; 2X ULN All patient must sign write informed consent Any prior chemotherapy , radiotherapy biologic therapy glioma . Any prior experimental therapy glioma . Multicentric glioma Other concurrent active malignancy ( exception cervical carcinoma situ basal cell ca skin ) . Serious medical psychiatric illness would opinion investigator interfere prescribe treatment . Pregnant breast feed woman . Refusal use effective contraception Inadequately control hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction unstable angina within 12 month prior Day 1 History stroke transient ischemic attack Significant vascular disease ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Day 1 History hemoptysis ( ≥ 1/2 teaspoon bright red blood per episode ) within 1 month prior Day 1 Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 treatment anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 History abdominal fistula gastrointestinal perforation within 6 month prior Day 1 Serious , nonhealing wound , active ulcer , untreated bone fracture Proteinuria demonstrate UPC ratio ≥ 1.0 screen Known hypersensitivity component bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radiation</keyword>
	<keyword>BEVACIZUMAB</keyword>
	<keyword>AVASTIN</keyword>
	<keyword>TEMOZOLOMIDE</keyword>
	<keyword>newly diagnose</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>GBM</keyword>
	<keyword>malignant glioma</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>08-126</keyword>
</DOC>